✦ LIBER ✦

PCV35 PHARMACOECONOMIC MODEL OF ENOXAPARIN VERSUS HEPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN MEDICAL PATIENTS

✍ Scribed by R Milani-Jr; W Follador; J Gonçalves; V Di Sena

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Individual patient data meta-analysis of

✍ S. LAPORTE; J. LIOTIER; L. BERTOLETTI; F.-X. KLEBER; G. F. PINEO; C. CHAPELLE; N 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 259 KB

Dalteparin versus Enoxaparin for the pre

✍ Okoye, O. T.; Gelbard, R.; Inaba, K.; Esparza, M.; Belzberg, H.; Talving, P.; Te 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 328 KB

PCV31 Cost-Effectiveness of Apixaban Ver

✍ Oh, J.J.; Shin, H.H.; Jung, H.; Park, J.H.; Ko, S.K. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PCV58 CLINICAL AND ECONOMIC ISSUES IN TH

✍ S Balu; FR Vogenberg; L Lichtig; P O'Connor 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Low-Molecular-Weight Heparin Versus Unfr

✍ Wilbur, K.; Lynd, L. D.; Sadatsafavi, M. 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 425 KB

PCV22: COST-EFFECTIVENESS OF ENOXAPARIN

✍ G de Lissovoy; P Subedi; V Nadipelli 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB